FINWIRES · TerminalLIVE
FINWIRES

LifeSci Capital Downgrades Crinetics Pharmaceuticals to Market Perform From Outperform, Price Target is $85

By

Crinetics Pharmaceuticals Inc (CRNX) has an average rating of overweight and mean price target of $83.18, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles